

# **Ninth Annual Pharmaceutical Regulatory and Compliance Congress Washington DC October 28, 2008**

## **Track VI Interactive Case Studies**

**Sue Egan**

**Vice President Compliance, International Sales and Marketing  
Organisation, AstraZeneca PLC, London, UK**

**Michael Shaw**

**Global Head, Ethics and Compliance, Novartis Oncology,  
Florham Park, NJ**

**Doreen F. Shulman**

**Vice President, Chief Compliance and Ethics Officer, Bristol-  
Myers Squibb**

**Keith M. Korenchuk**

**Covington & Burling LLP, Washington, DC**

# **Morning Track VI: Interactive International Case Studies**

## **Topics**

- 1. Distribution Channel Challenges;**
- 2. Third Party Oversight (Including Use of HCPs as Third Parties, and Anti-bribery and Anti-corruption Considerations);**
- 3. Organization of International Congresses and Conferences for HCP Attendance; and**
- 4. Management of Allegations and Investigations**

# **Interactive International Case Studies: Key Questions**

**What action would you take?**

**Other discussion items:**

**What are the compliance program  
elements implicated by this scenario?**

**What would you look for in evaluating the  
compliance framework?**

# **Afternoon Track V: Interactive Domestic Case Studies**

## **Topics**

- 1. Speaker Management Issues**
- 2. In-Office Interactions**
- 3. Conflicts of Interest with Customers**
- 4. Firewall Issues Related to  
Marketing/Medical Vendors**
- 5. PhRMA Code Issues Pre- and Post-  
implementation. and Investigations**

# **Interactive Domestic Case Studies: Key Questions**

**What action would you take?**

**Other discussion items:**

**What are the compliance program elements implicated by this scenario?**

**What would you look for in evaluating the compliance framework?**